Alnylam Pharmaceuticals, Inc. (ALNY) – aksjekurser og nyheter

Symboler Symboler	Pris	Endring	Endring (%)	Trend	Forrige pris ved stengetid	Åpne	Høy	Lav	Volum	Markedsverdi
SIXB Materials SIXB Materials	SIXB −1,21%	1 078,29	−13,22	−1,21%	—	1 091,51	1 090,40	1 090,40	1 075,55	—	—
SIXC Communications SIXC Communications	SIXC −0,26%	608,50	−1,61	−0,26%	—	610,11	610,11	610,29	606,17	—	—
SIXE Energy SIXE Energy	SIXE +0,76%	1 247,36	+9,38	+0,76%	—	1 237,98	1 237,83	1 252,41	1 225,03	—	—
SIXI Industrials SIXI Industrials	SIXI −0,99%	1 727,36	−17,35	−0,99%	—	1 744,71	1 740,95	1 747,29	1 721,57	—	—
SIXM Financials SIXM Financials	SIXM −0,50%	636,98	−3,20	−0,50%	—	640,18	639,92	643,19	636,28	—	—
SIXR Staples SIXR Staples	SIXR −0,64%	844,18	−5,40	−0,64%	—	849,58	845,27	851,68	841,28	—	—
SIXRE Real estate SIXRE Real estate	SIXRE −0,49%	216,41	−1,07	−0,49%	—	217,48	217,48	218,16	216,37	—	—
SIXT Technology SIXT Technology	SIXT −0,20%	3 254,25	−6,44	−0,20%	—	3 260,69	3 273,36	3 287,81	3 240,78	—	—
SIXU Utilities SIXU Utilities	SIXU −0,52%	937,58	−4,87	−0,52%	—	942,45	939,39	948,80	934,04	—	—
SIXV Health care SIXV Health care	SIXV −0,43%	1 460,45	−6,35	−0,43%	—	1 466,80	1 464,70	1 467,19	1 458,68	—	—
SIXY Discretionary SIXY Discretionary	SIXY −0,99%	2 373,75	−23,75	−0,99%	—	2 397,50	2 395,03	2 412,01	2 370,64	—	—

Inntekt Q1 2026 • utgitt • EPS overgikk forventningene +33,72% • Inntektene overgikk forventningene +4,71%

Se resultatene

ALNY:NASDAQ

Alnylam Pharmaceuticals, Inc.

293,52 USD

−0,87%

(−2,59) 1 D

4. mai, 12:53:45 GMT-4 · USD

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for ALNY …

Åpne

298,00 USD

Høy

300,49 USD

Lav

288,06 USD

Markedsverdi

39,20 mrd.

Volum

621,61k

P/E-forhold

69,91

52 u høy

495,55 USD

52 u lav

245,96 USD

EPS

4,20 USD

Beta

0,31

Utestående aksjer

133,43 mill.

Antall ansatte

Relaterte aksjer

Arrowhead Pharmaceuticals Inc

Nyhetssaker

Fra kilder på nettet

Yahoo! Finance Canada

for 4 timer siden

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Simply Wall Street

for 20 timer siden

Should Alnylam’s Billion‑Dollar Quarter and Return to Profitability Require Action From Alnylam Pharmaceuticals (ALNY) Investors?

MarketBeat

for 1 døgn siden

Hussman Strategic Advisors Inc. Buys Shares of 6,300 Alnylam Pharmaceuticals, Inc. $ALNY

The Globe and Mail

for 2 døgn siden

Raymond James Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)

Profil

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia

Om Alnylam Pharmaceuticals, Inc.

Administrerende direktør-

Ansatte2,5k

Grunnlagt14. juni 2002

Hovedkontor-

Sektor-

Nettstedalnylam.com

Alle verdier i USD	juni 2025	sep. 2025	des. 2025	mars 2026
Inntekt	773,69 mill.	1,25 mrd.	1,10 mrd.	1,17 mrd.
Varekostnad	142,95 mill.	200,15 mill.	267,72 mill.	207,52 mill.
Direkte driftskostnader	142,95 mill.	200,15 mill.	267,72 mill.	207,52 mill.
Utgifter til forskning og utvikling	323,62 mill.	358,81 mill.	372,22 mill.	368,47 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	323,31 mill.	322,08 mill.	325,37 mill.	322,55 mill.
Driftskostnader	646,94 mill.	680,89 mill.	697,59 mill.	691,02 mill.
Totale driftskostnader	789,89 mill.	881,04 mill.	965,32 mill.	898,54 mill.
Driftsinntekter	−16,20 mill.	367,98 mill.	131,72 mill.	268,64 mill.
Andre ikke-operasjonelle inntekter	−5,05 mill.	−74,15 mill.	92,98 mill.	−4,30 mill.
EBT inkludert uvanlige elementer	−35,36 mill.	238,97 mill.	161,14 mill.	221,65 mill.
EBT uten uvanlige elementer	−34,01 mill.	278,12 mill.	121,99 mill.	221,65 mill.
Kostnad for inntektsskatt	30,92 mill.	−12,12 mill.	−25,28 mill.	15,66 mill.
Faktisk avgiftssats	−87,45 %	−5,07 %	−15,69 %	7,07 %
Andre driftskostnader	-	-	-	-
Nettoinntekt	−66,28 mill.	251,08 mill.	186,42 mill.	205,99 mill.
Netto fortjenestemargin	−8,57 %	20,10 %	16,99 %	17,65 %
Resultat per aksje	0,32	2,90	1,25	1,99
Rente- og investeringsinntekter	27,49 mill.	28,68 mill.	26,63 mill.	26,60 mill.
Rentekostnader	−40,25 mill.	−44,40 mill.	−129,34 mill.	−69,29 mill.
Netto rentekostnader	−12,76 mill.	−15,72 mill.	−102,71 mill.	−42,69 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	−2,26 mill.	381,78 mill.	145,22 mill.	282,19 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning